Skip to main content

Table 1 Participant characteristics

From: Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials

Demographics Normal subjects (n=24) Heart failure subjects (n=25)
Age 28.6 ± 5.9 62.7 ± 14.3
Male 8 (33.3) 12 (48.0)
Hematocrit (%) 39.7 ± 3.8 40.5 ± 3.1
Serum creatinine (mg/dL) 0.75 ± 0.15 0.91 ± 0.28
eGFR (ml/min) 115.5 ± 21.5 82.3 ± 18.5
Medical history   
Diabetes Mellitus(%) 0 (0) 2 (8.0)
Smoking 3 (12.5) 1 (4.0)
Hypertension 0 (0) 14 (56.0)
Hyperlipidemia 0 (0) 8 (40.0)
LV function by CMR   
EDV (ml) 147.6 ± 31.8 214.8 ± 116.5
ESV (ml) 56.5 ± 14.9 133.9 ± 104.5
EF (%) 61.9 ± 4.0 42.1 ± 18.7
Mass (g) 111.0 ± 36.6 203.0 ± 110.6
Stroke volume (ml) 91.1 ± 19.4 81.0 ± 43.7
  1. Note: Mean and standard deviation or number and percentage as appropriate. LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction.